- Kane Biotech (KNE) has announced a C$1M non-brokered private placement
- It intends to use the proceeds for general working capital
- The company is currently pursuing ventures in animal care, surgery and wound care, as well as dermatology
- Kane Biotech is a biotechnology company focused on preventing and removing microbial biofilms
- Kane Biotech (KNE) is unchanged trading at $0.10 per share
Kane Biotech (KNE) has announced a C$1M non-brokered private placement.
It will offer up to 10,000,000 common shares priced at $0.10.
It intends to use the proceeds for general working capital.
The company’s technology and intellectual property portfolio is focused on biofilm-related ailments in animals, the dermatology space, and the surgery and wound care space.
“Kane continues to generate momentum across our three lines of business, each with significant and achievable milestones in 2022,” said Marc Edwards, Kane’s CEO. “I’m confident the proceeds of this offering will contribute significantly toward these milestones being realized.”
Kane Biotech is a biotechnology company focused on preventing and removing microbial biofilms.
Kane Biotech (KNE) is unchanged trading at $0.10 per share as of 11:29 am EST.
